Luba Greenwood is a distinguished executive, investor, and company builder with over 20 years of leadership in healthcare and technology, and extensive global board experience. She is the CEO of Gallop Oncology, a clinical stage biotech. She has founded and served as Managing Partner of Dana Farber Cancer Institute venture fund, and CEO and board chair of multiple life sciences companies including Kojin Tx. She is an Entrepreneur-in-Residence at PureTech, where she plays a key role in advancing oncology programs. Luba has a proven track record of building world-class teams and companies, leading over $15B in deals and investments across therapeutics, diagnostics, and life sciences globally. She has held leadership roles at Google (Verily) and Roche, where as VP of Global Business Development & M&A, she spearheaded diagnostics BD and established the East Coast Innovation Hub. Recognized as an industry thought leader, she advises CEOs of top academic institutions, including Dana-Farber Cancer Institute and Wyss Center. She serves on the Investor Committee for National Cancer Institute and contributes to NEJM Catalyst. Luba is a strategic leader in digital transformation, AI, M&A, financing, and governance, with expertise in scaling companies, guiding high-impact transactions, and driving innovation at the intersection of biotech and technology. A former lawyer at WilmerHale, Luba is an expert in regulatory, IP, and corporate law. She has served as a Harvard University lecturer and sits on multiple public and private boards, including In8Bio, BenchSci, Stalicla, Abcam (where she led its sale to Danaher), Closed Loop Medicine, and MassBio.

Julie is responsible for shaping and implementing the Boston IC strategy for programs and relationships across eastern North America. This includes innovative programs and deployment of business models that bring together all aspects of the innovation community including academia, venture, foundations and startups to create leveraged outreach and funding opportunities that can help expand the portfolio-building efforts and provide frameworks for seeding and de-risking technologies and assets. Julie has nearly 15 years of experience working in the Boston innovation community including three years at J&J, where she served as the Director of External Alliances for the World Without Disease Accelerator and Lung Cancer Initiatives and previously, the Janssen Human Microbiome Institute. Prior to J&J, Julie held various Program and Alliance Management roles in the Boston ecosystem including leading the Corporate Alliances team at Harvard’s Office of Technology Development. Julie began her biopharmaceutical career at Merck Research Laboratories, Boston, in Drug Metabolism and Pharmacokinetics. Julie holds an MBA from Boston University and BS from Villanova University.

John A. Harre, is a corporate and licensing attorney at Mintz who focuses his practice on the life sciences. He assists clients in the negotiation and drafting of licensing agreements and strategic collaborations and advises them on business matters involving intellectual property issues, including mergers and acquisitions, investments, and litigation. He primarily works with clients in the biotechnology, pharmaceuticals, and medical devices industries, drawing on 25 years of experience that spans in-house and consulting roles and private practice at several law firms. Prior to rejoining Mintz, John founded an intellectual property and transactional consultancy to advise life sciences companies, served as Vice President of Intellectual Property at Intarcia Therapeutics Inc. and preceding that served as Vice President of Intellectual Property and General Counsel at Archemix Corp. Prior to serving in-house John practiced patent counseling and enforcement at national law firms Sidley Austin, Fish & Richardson and Mintz Levin where he was a Partner in the Life Sciences intellectual property group. John graduated from the University of Missouri - St. Louis with a B.S. in Biology, received his M.S. in Biotechnology from the University of Tennessee - Knoxville and his law degree from the University of New Hampshire Franklin Pierce School of Law (formerly Franklin Pierce Law Center). John is a member of the bar of the Commonwealth of Massachusetts and the State of Texas and is admitted to practice before the United States Patent and Trademark Office. John is a co-chair of the Legal Working Group of the Mass Biotechnology Council and a member of the Dean’s Advisory Council at the University of New Hampshire Franklin Pierce School of Law.

Kat Holliday is Senior Associate Director for Technology Transactions in Harvard’s Office of Technology Development where her responsibilities include negotiating license and equity agreements for start-up companies forming around Harvard innovations, including those developed at Harvard Medical School, the Harvard Faculty of Arts and Sciences, the Harvard John A. Paulson School of Engineering and Applied Sciences and the Harvard T.H. Chan School of Public Health. Prior to OTD, Kat represented VionX Energy Corporation, a flow-battery, energy storage portfolio company of VantagePoint Capital Partners and Starwood Energy Group. She was previously a senior attorney in both the life sciences and clean energy practice groups at Mintz Levin in Boston, representing venture-backed companies and investors. She is a graduate of Harvard College and Harvard Law School.

Bart Newland is General Counsel of Atalanta Therapeutics, a Series-A funded startup focusing on novel therapies for neurological disorders. Bart previously has served as Senior Vice President and Chief IP Counsel of Biogen, Vice President for Intellectual Property of Genzyme, and as a shareholder of Rothwell, Figg, Ernst & Manbeck. Bart earned his J.D. at William and Mary Law School, where he currently serves on the Board of Directors of the Alumni Association. He earned his B.S. degree with honors in Microbiology from the University of Massachusetts.

Dan Shores is a Partner at Rothwell Figg and a founder of its Boston office. He has an extensive background in IP law in the biotech space and has been practicing in that space during the entirely of his 17-year career including in matters relating to small molecules, biosimilars, mRNA, LNP, and oligonucleotide technologies. Dan is passionate about helping his clients build robust patent portfolios, litigate matters (both as plaintiffs and defendants in the U.S. District Courts and in IPR and other post-grant proceedings), protect trade secrets, negotiate strategic collaborations, conduct due diligence and landscape investigations, and prepare for success in funding rounds and exits. Dan is a problem-solver who excels at deciphering key translational aspects of a broad array of technologies to maximize leverage in the context of clients’ desired implementation of such technologies whether as participants in dynamic markets or as first movers. Dan is a registered patent attorney licensed to practice before the United States Patent and Trademark Office, and is admitted to practice law in Massachusetts and in the District of Columbia. He is a member of the bars of the Supreme Court of the United States, United States Court of Appeals for the Federal Circuit, and United States District Court for the District of Massachusetts. Dan lives in Boston with his wife Lindsay, their daughter Audrey, and their two English Bulldogs Jarves and Rosie.